GLI2 and basal cell carcinoma: The FHL2-GLI2 fusion gene encompassing exons 8–13 of GLI2, recurrently detected in SSTs, as well as truncated (t) GLI2 lacking the repression domain were evaluated in multiple cell models, including immortalized mesenchymal stem cells (MSCs), HEK-293 cells, and in cells derived from cancers with known deregulation of the SHH pathway22,29,30, namely medulloblastoma (DAOY) and basal cell carcinoma (BCC) cells.